Dexcom (DXCM) stock
NASDAQ
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 1
- Market cap
- $31.5B
- As of Nov 5, 2026
- P/E
- 31.79x
- Trailing twelve months
- P/B
- 12.43x
- Latest reported equity
- P/S
- 6.17x
- Trailing twelve months
- ROE
- 39.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $31.5B
- As of Nov 5, 2026
- P/E
- 31.79x
- Trailing twelve months
- P/B
- 12.43x
- Latest reported equity
- P/S
- 6.17x
- Trailing twelve months
- ROE
- 39.1%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
31.79x
P/B
12.43x
P/S
6.17x
Earnings and dividend metrics▾
Earnings
EPS
$2.66
Earnings per share
BPS
$6.80
Book value per share
ROE
39.1%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $2.66 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $6.80 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 39.1%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue increased 11.2% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.21B+11.2%
$994M
Jul–Sep '24
$1.21B
Jul–Sep '25
$1.35B
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Oct 29, 2026.
- Earnings per share increased 2.9% from the same quarter a year earlier.
- Revenue increased 11.2% from the same quarter a year earlier.
- Operating income increased 34.6% from the same quarter a year earlier.
- Net income decreased 3.2% from the same quarter a year earlier.
Filed Oct 29, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Ashley Euan A.Director · Oct 30, 2026Gift2,389 shares · $0Avg. price $010,342 shares held after
- Stern SadieEVP Chief People & Culture Off · Oct 27, 2026Open-market sale2,565 shares · $202KAvg. price $78.62120,913 shares held after
- Brown Michael JonEVP Chief Legal Compliance Off · Oct 15, 2026Open-market sale1,700 shares · $145KAvg. price $85.4898,185 shares held after
- Stern SadieEVP Chief People & Culture Off · Sep 28, 2026Open-market sale2,565 shares · $221KAvg. price $86.15123,478 shares held after
- AUGUSTINOS NICHOLASDirector · Sep 15, 2026Open-market sale6,539 shares · $550KAvg. price $84.0429,293 shares held after
- Brown Michael JonEVP Chief Legal Compliance Off · Sep 15, 2026Open-market sale1,700 shares · $143KAvg. price $84.0499,885 shares held after
- AUGUSTINOS NICHOLASDirector · Sep 14, 2026Open-market sale1,550 shares · $130KAvg. price $84.0235,832 shares held after
- Sylvain Jereme MEVP, Chief Financal Officer · Sep 10, 2026Open-market sale3,638 shares · $303KAvg. price $83.27146,828 shares held after
- Boehnlein Glenn SDirector · Sep 10, 2026Grant or award5,841 shares · $0Avg. price $05,841 shares held after
- Stern SadieEVP Chief People & Culture Off · Aug 27, 2026Open-market sale2,565 shares · $227KAvg. price $88.37126,043 shares held after
- Stern SadieEVP Chief People & Culture Off · Aug 22, 2026Shares withheld for taxes1,451 shares · $134KAvg. price $92.34128,608 shares held after
- Leach Jacob StevenPresident, CEO, and Director · Aug 22, 2026Shares withheld for taxes1,451 shares · $134KAvg. price $92.34418,908 shares held after
- Sylvain Jereme MEVP, Chief Financal Officer · Aug 22, 2026Shares withheld for taxes1,451 shares · $134KAvg. price $92.34150,390 shares held after
- Brown Michael JonEVP Chief Legal Compliance Off · Aug 22, 2026Shares withheld for taxes1,451 shares · $134KAvg. price $92.34101,502 shares held after
- SAYER KEVIN RExecutive Chair · Aug 20, 2026Open-market sale26,756 shares · $2.4MAvg. price $90.0076
Show 3 price lots
- 19,308 shares × $89.706$1.7M
- 7,351 shares × $90.7811$667K
- 97 shares × $91.41$9K
- Brown Michael JonEVP Chief Legal Compliance Off · Aug 14, 2026Open-market sale1,700 shares · $156KAvg. price $91.93102,953 shares held after
- Heller Bridgette PDirector · Aug 12, 2026Open-market sale1,012 shares · $89KAvg. price $88.2929,570 shares held after
- AUGUSTINOS NICHOLASDirector · Aug 12, 2026Gift1,075 shares · $0Avg. price $037,382 shares held after
- FOLETTA MARK GDirector · Aug 3, 2026Open-market sale2,000 shares · $171KAvg. price $85.3248,852 shares held after
- FOLETTA MARK GDirector · Jul 31, 2026Open-market sale2,000 shares · $160KAvg. price $8050,852 shares held after
- SAYER KEVIN RExecutive Chair · Jul 20, 2026Open-market sale26,756 shares · $2.0MAvg. price $76.3193328,970 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary8-KThe company said revenue for Q3 2026 grew 11% year-over-year on a reported basis to $1.344 billion, up from $1.209 billion in Q3 2025. It said U.S. revenue grew 14% and international revenue grew 5%.Published Oct 29, 2026 · Filed Oct 29, 2026Read the summary →
- AI summary8-KDexcom said it held its 2026 Annual Meeting of Stockholders on May 27, 2026. As of the record date on April 1, 2026, 385,872,977 shares of the company's common stock were outstanding and entitled to vote, and 336,525,352 shares were present in person or represented by proxy, constituting a quorum for the transaction of business.Published Oct 2, 2026 · Filed May 28, 2026Read the summary →
- AI summary8-KThe company said it held its 2026 Investor Day in Mesa, Arizona, on May 14, 2026, discussing market opportunities, business strategy, innovation efforts and long-term financial outlook. It also posted an investor presentation and a replay of the webcast on its investor relations website.Published Oct 13, 2026 · Filed May 15, 2026Read the summary →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Dexcom (DXCM) stock information
NASDAQ
Dexcom (DXCM) is listed on NASDAQ. Its market capitalization is about $31.5B. On trailing-twelve-month earnings the P/E ratio is 31.79, and the P/B ratio is 12.43. Return on equity is 39.1%. These figures are computed in-house from official filings and are reference information only.
Dexcom — frequently asked questions
- What is the P/E ratio of Dexcom (DXCM)?
- On a trailing-twelve-month basis, DXCM trades at a P/E ratio of 31.79. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Dexcom?
- DXCM has a market capitalization of about $31.5B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.